Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ: SMMT )

23.76 -0.89 (-3.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,602,460
Open 25.00
Bid (Size) 23.49 (1)
Ask (Size) 23.89 (1)
Prev. Close 24.65
Today's Range 23.39 - 25.00
52wk Range 2.100 - 33.89
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
Via The Motley Fool
Why Summit Therapeutics Stock Is Jumping Today
Via The Motley Fool

Performance

YTD
+29.48%
+29.48%
1 Month
+23.24%
+23.24%
3 Month
+11.76%
+11.76%
6 Month
+105.71%
+105.71%
1 Year
+422.20%
+422.20%

More News

Read More
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Why Summit Therapeutics Rocketed 584% in 2024
Via The Motley Fool
Where Will Summit Therapeutics Be in 5 Years?
Via The Motley Fool
How Is The Market Feeling About Summit Therapeutics?
Via Benzinga
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Via Benzinga
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Via Benzinga
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
Prediction: These 3 Healthcare Stocks Will Soar in 2025
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2025
Via The Motley Fool
3 Stocks That Could Turn $1,000 into $5,000 by 2030
Via The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Via The Motley Fool
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
Via The Motley Fool
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Via The Motley Fool
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher
Via The Motley Fool
Warning: This Skyrocketing Stock Has a Hidden Risk
Via The Motley Fool
Summit Therapeutics to Present at Upcoming Investor Conferences
From Summit Therapeutics Inc.
Via Business Wire
3 Monster Stocks in the Making
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Via Investor's Business Daily
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.